Far-UVC efficiently inactivates an airborne pathogen in a room-sized chamber

Abstract Many infectious diseases, including COVID-19, are transmitted by airborne pathogens. There is a need for effective environmental control measures which, ideally, are not reliant on human behaviour. One potential solution is Far-UVC which can efficiently inactivate pathogens, such as coronaviruses and influenza, in air. When appropriately filtered, and because of its limited penetration, there is evidence that Far-UVC does not induce acute reactions in the skin or eyes, nor delayed effects such as skin cancer. While there is laboratory evidence for far-UVC efficacy, there is limited evidence in full-sized rooms. In the first study of its type, we show that Far-UVC deployed in a room-sized chamber effectively inactivates aerosolised Staphylococcus aureus. At a room ventilation rate of 3 air changes per hour (ACH), with 5 filtered sources the steady-state pathogen load was reduced by 92.1% providing an additional 35 equivalent air changes (eACH). This reduction was achieved using Far-UVC intensities consistent with current regulatory limits. Far-UVC is likely to be more effective against common airborne viruses, including SARS-CoV-2, and should thus be an effective and “hands-off” technology to reduce airborne disease transmission. The findings provide room-scale data to support the design and development of safe and effective Far-UVC systems.